brinzolamide: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
brinzolamide: clinical details
Prescribing considerations
- Licensed for adults with ocular hypertension or open-angle glaucoma in the specified circumstances.
- Not recommended in hepatic impairment because it has not been studied.
- Paediatric safety and efficacy are not established; the selected product is not recommended for children.
- Use caution in pseudoexfoliative or pigmentary glaucoma; use in narrow-angle glaucoma is not recommended.
- Systemic sulfonamide reactions remain possible despite ocular administration.
Contraindications and cautions
- Hypersensitivity to brinzolamide or an excipient
- Known sulfonamide hypersensitivity
- Severe renal impairment
- Hyperchloraemic acidosis
Monitoring
- Intraocular pressure and visual function
- Skin and systemic hypersensitivity reactions
- Corneal health, especially with dry eye, corneal disease, diabetes, contact-lens use or prolonged benzalkonium chloride exposure
- Renal risk and features of metabolic acidosis where clinically relevant
Clinical pharmacology
Brinzolamide selectively inhibits carbonic anhydrase II, reducing aqueous-humour secretion. It is systemically absorbed, binds to carbonic anhydrase in red blood cells, forms an active N-desethyl metabolite and is eliminated mainly through the kidneys.
Formulation and product differences
- The selected product is a white to off-white ophthalmic suspension and must be shaken before use.
- It contains benzalkonium chloride, which can irritate compromised corneas and discolour soft contact lenses.
- Bottle design and handling may vary between manufacturers; patients should follow the supplied leaflet.
- Fixed-combination eye drops containing brinzolamide have additional active ingredients and different precautions and contraindications.
brinzolamide preparations and strengths
Eye drops
Route: Ophthalmic
Strengths: 10 mg/mL
brinzolamide interactions
Systemic absorption is limited, but clinically relevant interactions remain possible.
Oral carbonic anhydrase inhibitors, such as acetazolamide
Combined use is not recommended because systemic effects, including acid–base disturbance, may be additive.
Strong CYP3A4 inhibitors, including itraconazole, ketoconazole, clotrimazole and ritonavir
They may reduce brinzolamide metabolism, so concurrent use warrants caution.
Other eye drops or eye ointments
Using preparations too close together may wash medicine from the eye; keep them separate and apply ointments last.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.